Literature DB >> 20087614

Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.

Tsutomu Hamasaki1, Yukihiro Kondo, Yoshihiko Ogata, Kazuhiro Yoshida, Go Kimura, Hiroyuki Shimizu, Taiji Nishimura.   

Abstract

We performed transurethral resection of the prostate (TUR-P) for a 66-year-old man with benign prostatic hyperplasia. Pathological examination diagnosed poorly differentiated urothelial carcinoma of the urethra with broad prostatic permeation. Random bladder biopsies showed no malignancy, but a second TUR-P revealed urothelial carcinoma in the prostate and bladder neck. Computed tomography (CT) showed lymph node metastases from para-aortic to right/left external iliac and left obturator nodes, so clinical stage T3N2M0 carcinoma of the prostatic urethra was diagnosed. Given the presence of lymph node metastases, neoadjuvant chemotherapy using cisplatin 70 mg/m(2), ifosfamide 1.2 g/m(2) and docetaxel 70 mg/m(2) (PIT) was considered. After chemotherapy, CT showed complete response (CR) of all lymph nodes. Local control in the bladder was considered to be good, so total prostatectomy and retroperitoneal lymph node dissection was selected instead of total cystoprostatectomy. Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized. No recurrences or metastases have been encountered as of 3 years and 5 months since surgery.

Entities:  

Mesh:

Year:  2010        PMID: 20087614     DOI: 10.1007/s10147-009-0006-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  12 in total

Review 1.  [Primary transitional cell carcinoma of prostate: a case report].

Authors:  M Uemura; R Imamura; H Inoue; K Nishimura; S Mizutani; S Miyoshi; T Mise
Journal:  Hinyokika Kiyo       Date:  2000-07

2.  CARCINOMA ORIGINATING IN DUCTS SURROUNDING THE PROSTATIC URETHRA.

Authors:  N ENDE; L P WOODS; H S SHELLEY
Journal:  Am J Clin Pathol       Date:  1963-08       Impact factor: 2.493

3.  Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma.

Authors:  J L Pariente; L Bordenave; P Michel; M J Latapie; D Ducassou; M Le Guillou
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

4.  Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.

Authors:  D F Bajorin; J A McCaffrey; P M Dodd; S Hilton; M Mazumdar; W K Kelly; H Herr; H I Scher; E Icasiano; G Higgins
Journal:  Cancer       Date:  2000-04-01       Impact factor: 6.860

5.  Intraductal carcinoma of the prostate gland.

Authors:  R K Rhamy; R D Buchanan; M J Spalding
Journal:  J Urol       Date:  1973-03       Impact factor: 7.450

6.  Transitional cell carcinoma of the prostate.

Authors:  D Kirk; C E Hinton; C Shaldon
Journal:  Br J Urol       Date:  1979-12

7.  Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy.

Authors:  Charalampos Andreadis; Stavros Touloupidis; Grammati Galaktidou; Alexandros H Kortsaris; Anastasios Boutis; Despina Mouratidou
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

8.  A clinicopathologic analysis of urothelial carcinomas diagnosed on prostate needle biopsy.

Authors:  B R Oliai; H Kahane; J I Epstein
Journal:  Am J Surg Pathol       Date:  2001-06       Impact factor: 6.394

9.  Clinical evaluation of soluble cytokeratin 19 fragments (CYFRA 21-1) in serum and urine of patients with bladder cancer.

Authors:  Y Senga; G Kimura; T Hattori; K Yoshida
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

10.  Primary transitional cell carcinoma of prostate.

Authors:  G S Nicolaisen; R D Williams
Journal:  Urology       Date:  1984-12       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.